The information contained in this section of the site is intended for US healthcare professionals only.

Are you a US healthcare professional?

You are now leaving SYMDEKO.com. You will be redirected to Facebook.com.

You are now leaving SYMDEKO.com. You will be redirected to VertexGPS.com.

You are now leaving SYMDEKO.com. You will be redirected to VertexGPS.com.

RESULTS FOR PEOPLE AGE 12 YEARS AND OLDER

RESULTS FOR PEOPLE AGE 12 YEARS AND OLDER

Select a tab below to learn about the study results in people age 12 years and older.

F508del/F508del

Other responsive mutations

Aiden age 13, with gene mutation F508del/F508del

SYMDEKO is for people with cystic fibrosis (CF) age 6 years and older with 2 copies of the F508del mutation in the CF gene or with at least 1 mutation in the CF gene that is responsive to treatment with SYMDEKO. It is not known if SYMDEKO is safe and effective in patients younger than 6 years of age.

Keep in mind, results shown are an average for all people studied and differed among individuals. You or your child may have a different experience.

Study details

In a clinical study of 504 people with CF, SYMDEKO and placebo were compared to determine the possible benefits and risks of SYMDEKO. Participants were age 12 years and older with 2 copies of the F508del mutation in the CF gene.

  • 248 people took SYMDEKO and 256 took placebo every 12 hours with fat-containing food for 24 weeks (~6 months)
  • Participants continued to take their other prescribed CF therapies

SYMDEKO improved lung function and reduced pulmonary exacerbations

pair of lungs

Lung function (FEV1)*

through 24 weeks
4 PERCENTAGE POINT
IMPROVEMENT
VS PLACEBO

Improved lung function by 4 percentage points on average compared with those who took placebo.

change in lung function over time: SYMDEKO vs placebo
lung function chart

lung function chart labels

Keep in mind, results shown are an average for all people studied and differed among individuals. You or your child may have a different experience.

acute worsening of symptoms

Pulmonary exacerbations

through 24 weeks
DECREASED BY
35%
VS PLACEBO

Lowered the chance of having a pulmonary exacerbation by 35% on average compared with those who took placebo.

Additional clinical study results

bathroom scale and tape measure

Body Mass Index (BMI)

at 24 weeks

Increased by 0.06 kg/m2 on average compared with those who took placebo.

  • For example, a person who is 5’4” and 110 pounds would gain 0.35 pounds, or a person who is 5’10” and 160 pounds would gain 0.42 pounds
  • It cannot be determined if this change was due to SYMDEKO
person breathing out

CF Respiratory Symptoms

through 24 weeks

5.1 point change on average in certain CF respiratory symptoms compared with those who took placebo

  • It cannot be determined if this change was due to SYMDEKO

A tool was used to measure CF respiratory symptoms including cough, difficulty breathing, and amount of mucus coughed up.

FEV1=percent predicted forced expiratory volume in 1 second
Respiratory symptoms were measured by the CFQ-R Respiratory Domain score, which is a tool used in research to measure CF respiratory symptoms.
Girl with other responsive gene mutation

SYMDEKO is for people with cystic fibrosis (CF) age 6 years and older with 2 copies of the F508del mutation in the CF gene or with at least 1 mutation in the CF gene that is responsive to treatment with SYMDEKO. It is not known if SYMDEKO is safe and effective in patients younger than 6 years of age.

Keep in mind, results shown are an average for all people studied and differed among individuals and mutations. You or your child may have a different experience.

Study details

In a clinical study of 244 people with CF, SYMDEKO was compared with ivacaftor and placebo to determine the possible benefits and risks of SYMDEKO. Participants were age 12 years and older with the F508del mutation and a second mutation in the CF gene predicted to respond to SYMDEKO.

Mutations included in the clinical study
711+3AG

c.579+3A>G

A455E

c.1364C>A

E831X

c.2491G>T

R347H

c.1040G>A

S977F

c.2930C>T

2789+5GA

c.2657+5G>A

D110H

c.328G>C

L206W

c.617T>G

R352Q

c.1055G>A

3272-26AG

c.3140-26A>G

D579G

c.1736A>G

P67L

c.200C>T

R1070W

c.3208C>T

3849+10kbCT

c.3718-2477C>T

D1152H

c.3454G>C

R117C

c.349C>T

S945L

c.2834C>T

711+3AG

c.579+3A>G

L206W

c.617T>G

2789+5GA

c.2657+5G>A

P67L

c.200C>T

3272-26AG

c.3140-26A>G

R117C

c.349C>T

3849+10kbCT

c.3718-2477C>T

R347H

c.1040G>A

A455E

c.1364C>A

R352Q

c.1055G>A

D110H

c.328G>C

R1070W

c.3208C>T

D579G

c.1736A>G

S945L

c.2834C>T

D1152H

c.3454G>C

S977F

c.2930C>T

E831X

c.2491G>T

  • Each person had two 8-week treatment periods where they took either SYMDEKO, ivacaftor, or placebo every 12 hours with fat-containing food. Participants received 2 of the 3 possible treatments after completing both treatment periods
    • 161 patients took SYMDEKO, 156 patients took ivacaftor, and 161 patients took placebo
    • Between treatment periods, there was an 8-week washout period where they did not take SYMDEKO, ivacaftor, or placebo
  • Participants continued to take their other prescribed CF therapies

SYMDEKO improved lung function

pair of lungs

Lung function (FEV1)*

average at Weeks 4 and 8
6.8

PERCENTAGE POINT
IMPROVEMENT
VS PLACEBO

2.1

PERCENTAGE POINT
IMPROVEMENT
VS IVACAFTOR

Improved lung function overall by an average of 6.8 percentage points compared with placebo. Additionally, improved lung function by an average of 2.1 percentage points compared with ivacaftor.

change in lung function over time: tezacaftor/ivacaftor vs ivacaftor vs placebo
change in lung function over time: tezacaftor/ivacaftor vs ivacaftor vs placebo

lung function chart labels

Changes in lung function varied by mutations (range -1.0 to 10.1 percentage points compared with placebo) and individuals.

Keep in mind, all results shown are an average of all people studied and different among individuals and mutations. You or your child may have a different experience.

Additional clinical study results

person breathing out

CF Respiratory Symptoms

average at Weeks 4 and 8

11.1 point overall improvement on average in CF respiratory symptoms compared with placebo

1.4 point change on average in CF respiratory symptoms compared with ivacaftor

  • It cannot be determined whether this change was due to SYMDEKO

Changes in CF respiratory symptoms varied by mutations (range -11.1 to 29.2 points compared with placebo).

A tool was used to measure CF respiratory symptoms including cough, difficulty breathing, and amount of mucus coughed up.

FEV1=percent predicted forced expiratry volume in 1 second
Respiratory symptoms were measured by the CFQ-R Respiratory Domain score, which is a tool used in research to measure CF respiratory symptoms.

Important Safety Information

Do not take SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) if you take certain medicines or herbal supplements such as:

  • antibiotics such as rifampin (Rifamate®, Rifater®) or rifabutin (Mycobutin®)
  • seizure medicines such as phenobarbital, carbamazepine (Tegretol®, Carbatrol®, Equetro®), or phenytoin (Dilantin®, Phenytek®)
  • St. John’s wort

Talk to your doctor before taking SYMDEKO if you take any of the medicines or herbal supplements listed above.

Before taking SYMDEKO, tell your doctor about all of your medical conditions, including if you:

  • have or have had liver problems
  • have kidney problems
  • are pregnant or plan to become pregnant. It is not known if SYMDEKO will harm your unborn baby. You and your doctor should decide if you will take SYMDEKO while you are pregnant
  • are breastfeeding or planning to breastfeed. It is not known if SYMDEKO passes into your breast milk. You and your doctor should decide if you will take SYMDEKO while you are breastfeeding

SYMDEKO may affect the way other medicines work, and other medicines may affect how SYMDEKO works.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, because the dose of SYMDEKO may need to be adjusted when taken with certain medicines.

Especially tell your doctor if you take:
  • antifungal medicines such as ketoconazole (e.g., Nizoral®), itraconazole (e.g., Sporanox®), posaconazole (e.g., Noxafil®), voriconazole (e.g., Vfend®), or fluconazole (e.g., Diflucan®)
  • antibiotics such as telithromycin (e.g., Ketek®), clarithromycin (e.g., Biaxin®), or erythromycin (e.g., Ery-Tab®)

What should I avoid while taking SYMDEKO?

  • SYMDEKO can cause dizziness in some people who take it. Do not drive a car, use machinery, or do anything that needs you to be alert until you know how SYMDEKO affects you
  • Avoid food or drink that contains grapefruit or Seville oranges while you are taking SYMDEKO

What are the possible side effects of SYMDEKO?

SYMDEKO can cause serious side effects, including:
  • High liver enzymes in the blood have been reported in people treated with SYMDEKO or treated with ivacaftor alone. Your doctor will do blood tests to check your liver:
    • before you start SYMDEKO
    • every 3 months during your first year of taking SYMDEKO
    • every year while you are taking SYMDEKO

    Your doctor may do blood tests to check the liver more often if you have had high liver enzymes in your blood in the past.

    Call your doctor right away if you have any of the following symptoms of liver problems:
    • pain or discomfort in the upper right stomach (abdominal) area
    • yellowing of your skin or the white part of your eyes
    • loss of appetite
    • nausea or vomiting
    • dark, amber-colored urine

  • Abnormality of the eye lens (cataract) in some children and adolescents treated with SYMDEKO or with ivacaftor alone. If you are a child or adolescent, your doctor should perform eye examinations before and during treatment with SYMDEKO to look for cataracts

The most common side effects of SYMDEKO include headache, nausea, sinus congestion, and dizziness.

These are not all the possible side effects of SYMDEKO. Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA at 1-800-FDA-1088.

For further information, please see full Prescribing Information, including Patient Information.

What is SYMDEKO?

SYMDEKO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with SYMDEKO.

Talk to your doctor to learn if you have an indicated CF gene mutation.

It is not known if SYMDEKO is safe and effective in children under 6 years of age.

What is SYMDEKO?

SYMDEKO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with SYMDEKO.

Talk to your doctor to learn if you have an indicated CF gene mutation.

It is not known if SYMDEKO is safe and effective in children under 12 years of age.

Click for full safety